{"slug":"clinical","open_questions":[{"id":"open_question-clinical-trials-alzheimers-disease-cbe4c742","title":"API Generation AD:","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-clinical-trials-alzheimers-disease-ebb88aba","title":"DIAN-TU-EXR:","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-6859c1f3-0176-4332-9c07-714154926e8b","title":"Are effects disease-modifying or purely symptomatic?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-e2ed86e9-e942-4282-bfdb-dde339df78e1","title":"Long-term durability of benefits?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-clinical-trials-fnirs-neurofeedback-pd-nct05800470-217c5273","title":"Home-based systems","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-clinical-trials-fnirs-neurofeedback-pd-nct05800470-bd117cf8","title":"Combination with other neuromodulation","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-clinical-trials-interleukin-2-alzheimers-nct06096090-0a2d7261","title":"Microbiome modulation","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-clinical-trials-arc-im-adaptive-neurostimulation-parkinsons-7bfe1a4d","title":"Multi-target stimulation","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-clinical-trials-nct03899298-8370eecf","title":"Small molecule priming","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-clinical-trials-nct03899298-01e8673c","title":"With small molecules","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-clinical-trials-nct03899298-f47ee03f","title":"With rehabilitation","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-clinical-trials-nct03899298-0f7c8355","title":"With devices","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-clinical-trials-vcycle-virtual-cycling-nct04804202-22ad9b4a","title":"VR + Gene Therapy","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-clinical-trials-vcycle-virtual-cycling-nct04804202-8c7866f0","title":"Biomarker Selection","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-clinical-trials-flornaptitril-pet-alzheimers-da213fd9","title":"Longitudinal Changes","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-clinical-trials-nct06750432-pmn310-anti-amyloid-decd8c4a","title":"Biomarker Companion Diagnostics","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-clinical-trials-nct06750432-pmn310-anti-amyloid-f61491fa","title":"Combination Approaches","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-clinical-trials-aro-mapt-sc-tau-aso-nct07221344-e75db0ad","title":"Other tauopathies","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-clinical-trials-flornaptitril-pet-alzheimers-a554c48a","title":"Optimal Imaging Protocols","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-clinical-trials-alzheimers-disease-104eca47","title":"AHEAD 3 (NCT05900981):","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5}],"open_questions_total":20,"knowledge_gaps":[{"id":"gap-debate-20260410-095530-bad6da26","title":"What is the optimal timing window for gut-brain axis interventions relative to AD disease progression stages?","domain":"clinical neurology","status":"open","importance_elo":1000.0},{"id":"gap-debate-20260410-095546-25ab0ace","title":"Can stellate neuron-specific biomarkers predict therapeutic response in early AD intervention trials?","domain":"clinical research","status":"open","importance_elo":1000.0},{"id":"gap-debate-20260410-110746-cea33119","title":"What is the optimal timing window for gut barrier interventions to prevent AD pathology progression?","domain":"clinical translation","status":"open","importance_elo":1000.0},{"id":"gap-debate-20260410-111118-2a4f0a58","title":"Can qualitative research methods be systematically integrated into neurodegeneration biomarker validation studies?","domain":"clinical research methodology","status":"open","importance_elo":1000.0},{"id":"gap-debate-20260417-032954-942d73b1","title":"What biomarkers can stratify ALS patients most likely to respond to ferroptosis-targeted therapies?","domain":"clinical research","status":"open","importance_elo":1000.0},{"id":"gap-debate-20260410-095556-52e60b66","title":"Why have antioxidant approaches consistently failed in tauopathies despite oxidative stress involvement?","domain":"clinical neuroscience","status":"open","importance_elo":1000.0},{"id":"gap-pubmed-20260410-191132-87ccdbde","title":"Can randomized controlled trials confirm the neuroprotective effects observed in this retrospective cohort?","domain":"clinical neuroscience","status":"open","importance_elo":1000.0}],"gap_count":7,"landscape":null,"hypothesis_count":7,"personas":[{"id":"theorist","name":"Theorist","type":"debater","icon":"🧠","color":"#4fc3f7","debate_count":444},{"id":"skeptic","name":"Skeptic","type":"debater","icon":"⚠️","color":"#ffd54f","debate_count":443},{"id":"domain_expert","name":"Domain Expert","type":"debater","icon":"💊","color":"#81c784","debate_count":427},{"id":"synthesizer","name":"Synthesizer","type":"analyst","icon":"📊","color":"#ce93d8","debate_count":387},{"id":"clinical_trialist","name":"Clinical Trialist","type":"reviewer","icon":"📋","color":"#4dd0e1","debate_count":20},{"id":"computational_biologist","name":"Computational Biologist","type":"analyst","icon":"🧬","color":"#7986cb","debate_count":18},{"id":"ethicist","name":"Ethicist","type":"reviewer","icon":"⚖️","color":"#f48fb1","debate_count":8},{"id":"hongkui-zeng","name":"Hongkui Zeng","type":"debater","icon":"🧬","color":"#66bb6a","debate_count":7},{"id":"medicinal_chemist","name":"Medicinal Chemist","type":"builder","icon":"🧪","color":"#aed581","debate_count":7}]}